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Abstract
Background: Despite advances in surgical aggressiveness and conventional chemotherapy, ovarian cancer remains
the most lethal cause of gynecologic cancer mortality; consequently there is a need for new therapeutic agents
and innovative treatment paradigms for the treatment of ovarian cancer. Several studies have demonstrated that
ovarian cancer is an immunogenic disease and immunotherapy represents a promising and novel approach that
has not been completely evaluated in ovarian cancer. Our objective was to evaluate the anti-tumor activity of an
oncolytic herpes simplex virus “armed” with murine interleukin-12 and its ability to elicit tumor-specific immune
responses. We evaluated the ability of interleukin−12-expressing and control oncolytic herpes simplex virus to kill
murine and human ovarian cancer cell lines in vitro. We also administered interleukin−12-expressing oncolytic
herpes simplex virus to the peritoneal cavity of mice that had developed spontaneous, metastatic ovarian cancer
and determined overall survival and tumor burden at 95 days. We used flow cytometry to quantify the tumor
antigen-specific CD8+ T cell response in the omentum and peritoneal cavity.
Results: All ovarian cancer cell lines demonstrated susceptibility to oncolytic herpes simplex virus in vitro. Compared
to controls, mice treated with interleukin−12-expressing oncolytic herpes simplex virus demonstrated a more robust
tumor antigen-specific CD8+ T-cell immune response in the omentum (471.6 cells vs 33.1 cells; p = 0.02) and peritoneal
cavity (962.3 cells vs 179.5 cells; p = 0.05). Compared to controls, mice treated with interleukin−12-expressing oncolytic
herpes simplex virus were more likely to control ovarian cancer metastases (81.2 % vs 18.2 %; p = 0.008) and had a
significantly longer overall survival (p = 0.02). Finally, five of 6 mice treated with interleukin−12-expressing oHSV had no
evidence of metastatic tumor when euthanized at 6 months, compared to two of 4 mice treated with sterile
phosphate buffer solution.
Conclusion: Our pilot study demonstrates that an interleukin−12-expressing oncolytic herpes simplex virus effectively kills
both murine and human ovarian cancer cell lines and promotes tumor antigen-specific CD8+ T-cell responses in the
peritoneal cavity and omentum, leading to reduced peritoneal metastasis and improved survival in a mouse model.
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Background
Ovarian cancer remains the most lethal cause of gyneco-
logic cancer mortality with a median 5-year survival of
45 % for all stages. The American Cancer Society esti-
mated that 21,290 women will be diagnosed with ovarian
cancer in 2015 and that 14,180 will die of the disease [1].
Although advances in surgical resection and conventional
chemotherapy have improved progression-free survival for
the majority of women, most will eventually develop
resistance to traditional cytotoxic chemotherapies and
succumb to their disease [2]. Thus, there is a clear and
urgent need for new therapeutic agents and innovative
treatment paradigms for women with ovarian cancer.
Immunotherapy is a promising and novel approach not
fully evaluated in the context of ovarian cancer. Ovarian
cancer is an immunogenic disease as demonstrated by the
expression of tumor-associated antigens such as mesothe-
lin, CA-125, MUC-1, NY-ESO-1, and HER2/NEU, along
with the discovery of antibodies and T-cells isolated from
peripheral blood of ovarian cancer patients that react with
these antigens [3]. Immunotherapy represents an innova-
tive approach as a therapeutic modality [4, 5]. Several
investigators have demonstrated that immune response in
ovarian cancer correlates with patient outcomes. For
example, the presence of tumor infiltrating lymphocytes
(TILs), particularly CD8+ TILs, is associated with im-
proved overall survival in women with advanced ovarian
cancer [6–8]. Conversely, others have demonstrated that a
lack of TILs correlates with worse outcomes and resist-
ance to chemotherapy [9], suggesting that the cytotoxic
effects of chemotherapy may be aided by CD8+ T-cells
responding to released tumor- associated antigens [10].
Unfortunately, not all T-cells promote immunity, as the
recruitment of immunosuppressive regulatory T-cells
(Tregs), correlates with reduced survival in ovarian cancer
[11]. Thus, there appears to be a clear rationale for evalu-
ating virus-mediated immunotherapy in ovarian cancer. It
is our contention that oncolytic HSV that expresses a
potent cytokine, Interleukin-12, would accomplish three
important intratumoral changes: i) direct tumor cell lysis
by the virus, ii) generation of a tumor debris field and
increased exposure of tumor-associated antigens to im-
mune effector cells allowing for Matzinger “danger signal”
immune activation, and iii) augmentation of TH1-type
anti-tumor response to antigen and co-stimulation by
intratumoral IL-12 expression (Signal 3) [12–14].
Importantly, immune responses to ovarian cancer must
be targeted to the peritoneal cavity and the omentum,
which are the primary sites of ovarian cancer metastasis
[15]. However, the peritoneal cavity is a unique immuno-
logic environment, with an abundance of interleukin
(IL)-10-producing macrophages and B cells as well as
Tregs [16, 17]. Ovarian carcinoma may take advantage of
the unique properties of the omentum to suppress
development of anti-tumor immunity [15]. Thus, novel
treatments for ovarian carcinoma must be effective in the
unique immunological environment of the peritoneal
cavity and omentum.
Oncolytic viruses are designed to selectively replicate
in tumor cells and induce cell death through apoptosis,
autophagy, and/or necrosis. In addition to the cytotoxic
effects achieved by oncolytic viruses, they also illicit an
antitumor effect through the production of neoantigens
and provide subsequent anti-tumor immune response
[12, 13, 18]. These immunogenic effects can be
enhanced when oncolytic viruses are transformed to
express co-stimulatory cytokines, such as IL-12. Clinical
trials have evaluated and confirmed the safety of oncoly-
tic viruses, such as adenovirus, reovirus, and measles
virus for the treatment of ovarian carcinoma [19, 20].
Genetically engineered oncolytic herpes simplex viruses
(oHSV) have also demonstrated an ability to infect and
kill several cancer cell types, including ovarian and
melanoma [21–23]. Investigators have modified oHSV to
incorporate various constructs in order to enhance their
cytotoxic and immune-stimulating effects. For example,
preclinical studies show that IL-12 expressing oHSV
(M002) is effective in murine and primate models of
brain tumors and enhances the influx of both CD4+ and
CD8+ T-cells [12, 24]. Furthermore, the oHSV M002 has
been shown to mediate superior anti-tumor effects when
compared to other non-cytokine HSVs [13]. These find-
ings, in addition to our prior preclinical studies of M002
in other tumor models, provided the rational for investi-
gating the IL-12 oHSVs in ovarian cancer [12, 13].
Specifically, we tested in this pilot whether IL-12 ex-
pressing oHSV strains could infect and kill ovarian can-
cer cell lines in vitro and promote anti-tumor immunity
in an ovarian cancer mouse model. Our results demon-
strated that each evaluated ovarian cancer cell line
exhibited sensitivity to oHSV when tested in vitro. Mice
treated with intraperitoneal (IP) IL-12 expressing oHSV
demonstrated a more robust tumor antigen-specific CD8
+ T-cell immune response within all evaluated tissues.
Finally, mice treated with IL-12 expressing oHSV were
more likely to control ovarian cancer metastases and
had a significantly longer overall survival.
Methods
Oncolytic herpes simplex viruses (oHSVs)
Wild-type herpes simplex virus (HSV) causes potentially
life-threatening encephalitis, consequently attenuation is a
prerequisite of oncolytic HSV development. To accommo-
date this effect, several mutations within the following
viral genes within HSV have been described: thymidine
kinase [25], ribonucleotide reductase [26], UTPase [27], or
γ 34.5 gene [28, 29]. In our study, we utilized the genetic-
ally engineered oHSV strains, R3659 and G207, with
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deletions in the diploid γ34.5 gene (Δγ34.5 oHSV) [30].
The native γ34.5 gene exists in two copies and normally
encodes a multifunctional protein of 263 amino acids that
enable the HSV to efficiently replicate in infected cells
even in the presence of a host antiviral response. In wild
type HSV infected non-cancerous cells, protein kinase R is
stimulated by the production of double stranded viral
RNAs and phosphorylates eukaryotic initiation factor 2
alpha (eIF-2α) to block protein synthesis. Wild-type HSV
uses the γ34.5 gene product (Infected Cell Protein 34.5) to
bind Protein Phosphatase-1 and directing it to de-
phosphorylate eIF-2α, thus reactivating eIF-2α.. Host cell
protein shutoff is reversed allowing for viral replication to
proceed. γ34.5-deleted HSVs are safe in normal cells since
it cannot replicate efficiently; however, tumor cells inacti-
vate PKR upstream generally by activating or mutating ras
which makes them very susceptible to infection and
unfettered replication by γ34.5-deleted HSVs.
In our experiments we also utilized ψ34.5 gene modi-
fied oHSVs engineered to express either murine IL-12
(M002), [12, 13] or human IL-12, (M032) as a means to
augment the host immune responses to these viruses
[24, 31]. Using an intracranial syngeneic neuroblastoma
murine model, Parker et al. demonstrated improved
survival in mice treated with M002, along with an influx
of CD8+ T-cells [12].
Ovarian cancer cell lines
We utilized several ovarian adenocarcinoma cell lines,
both murine and human, along with ovarian cancer cells
harvested from female MISIIR-TAg mice, a spontaneous
ovarian cancer mouse model, to assess the in vitro cyto-
toxicity of oHSV. We specifically evaluated four syngeneic
models of transplantable murine ovarian adenocarcinoma:
ID8, Ig10, M0505, and STOSE [32–34]. STOSE cells are a
spontaneously transformed derivative of the immortalized
but non-tumorigenic M0505 cell line (courtesy of Dr.
BarbaraVanderhyden, Ottowa Hospital Research Institute)
[35], which share many molecular properties with human
epithelial ovarian carcinoma. Established paired chemo-
sensitive, A2780ip2, HEYA8, and SKOV3ip1, and chemo-
resistant, A2780cp20, HeyA8MDR, and SKOV3TRip2,
(courtesy of Dr. Charles Landen, University of Virginia)
human ovarian adenocarcinoma cell lines were treated
with oHSV [36, 37]. Individual cell lines were incubated in
225 mL sterile flasks in RPMI plus 10 % FBS as liquid
medium (Hyclone, Logan, UT).
Assessment of in vitro oHSV cytotoxic effect
To assay the cytotoxic effects of oHSV, ovarian cancer
cells were harvested from tissue culture after trypsiniza-
tion, re-suspended in equal volume culture medium and
spun down using a centrifuge at (180 × G, 6 min, ambi-
ent). The excess liquid was aspirated and the pellet was
re-suspended in tissue culture, and a 0.04 % trypan blue
exclusion count was performed to calculate the number
of viable (dye-excluding) cells per mL. The cell concen-
tration was adjusted so that 4,000 cells were plated in
wells A2-H12 of a 96 well plate. The cells were incu-
bated overnight and a 7 tube dilutional series for each
virus was performed, evaluating 100, 33, 10, 3.3, 1.0,
0.33, and 0.1 plaque forming units per cell (pfu/well).
Two replicate 96 well plates were tested for each virus.
The control well, A1, received 200 μL of culture medium
only, to “blank” the spectrophotometer and to represent
100 % cytotoxicity, while wells A2-A12 received 100 μL of
medium to represent the 100 % (maximum) cell survival
group as no virus was added to each this row. Beginning
with the most dilute virus (0.01 pfu/cell), 100 μL of virus
was added to each well of row B of the plate and contin-
ued down the plate for each successive virus concentra-
tion. Plates were reincubated for 48 h at which point
25 μL of sterile Alamar Blue dye was added to each well
and the BioTek spectrophotometer was used to determine
the corrected optical density (OD562–OD590) of each well
4 and 8 hours after the dye was added. Mean OD values
for each virus dilution was used to construct a dose
response plot and the number of plaque forming units of
virus needed to kill 50 % of the cells (PFU/TD50) was
calculated utilizing a regression analysis for the linear
portion of the sigmoidal plots. Triplicate wells for each
virus were obtained and the PFU/TD50 was averaged for
all three experiments.
Mouse husbandry and genotyping
MISIIR-TAg mice [38] were obtained from Dr. Denise
Connolly, Fox Chase Cancer Center. Transgene-positive
male mice were bred to non-transgenic C57BL/6 females
and the offspring were genotyped by PCR using DNA
extracted from ear punches. DNA was subjected to PCR
using the primers, TGCATGGTGTACAACATTCC and
TTGGGACTGTGAATCAATGCC, and Expand High
Fidelity taq polymerase (Roche) with 30 cycles of 95 °C
for 30s, 60 °C for 30s and 72 °C for 30s. The resulting
amplicon was analyzed by agarose gel electrophoresis
and a band of 773 bp was indicative of a positive reac-
tion. Only transgene positive females were used in our
study since these mice are known to develop spontan-
eous ovarian cancer with metastases to the omentum as
early as 7 weeks [39]. All experiments involving mice
were approved by the University of Alabama at Birming-
ham Institutional Animal Care and Use Committee.
Assessment of anti-tumor effect in a spontaneous ovarian
cancer in vivo model
Transgene positive female MISIIR-TAg mice (n = 22) were
randomized into control and experimental groups at 3 weeks
of age and underwent bilateral salpingo-oophorectomy at
Thomas et al. Journal of Ovarian Research  (2016) 9:70 Page 3 of 11
10 weeks. 1, 2, and 3 weeks after surgery, mice received
either 1 × 107 PFU of M002 oHSV or 500 ul phosphate
buffer solution (PBS) in the peritoneal cavity. The oHSV
dose (1 × 107 PFU) used in this study was noted in previous
experiments to be the maximum tolerated dose in the
HSV-sensitive A/J mouse strain [12]. Mice were monitored
using standard American Association for Laboratory Animal
Science (IACUC) body condition scoring until they reached
the study endpoint of 6 months; remaining mice were
euthanized and metastatic disease, if present, was measured.
Mice with a body condition score of less than 2 were
euthanized and counted as “dead” if there was evidence of
tumor at the time of necropsy. Overall survival (OS) was
defined as time from bilateral salpingo-oophorectomy to
death from any cause.
Assessment of immune response in a spontaneous
ovarian cancer in vivo model
In a separate assessment we randomized 36 additional
MISIIR-TAg mice to receive either 1 × 107 PFU of M002
oHSV or 500 ul PBS IP and quantified the number of
tumor antigen-specific CD8+ T-cells in the omentum,
peritoneal cavity, lymph nodes, and spleen at 7 or 10 days.
Specifically, cell suspensions were obtained for these
studies by mechanical disruption from mediastinal lymph
nodes and spleen, and by enzymatic digestion of the
omentum (5 mg/mL collagenase-DNase I mix (Sigma
Aldrich®, Inc. St. Louis, MO) in DMEM media at 37 °C).
Cells from the peritoneal cavity for these studies were col-
lected from ice-cold PBS washings obtained from the peri-
toneal cavity. All cell suspensions were blocked with Fc
block for 10 min at 4 °C, followed by incubation with anti-
CD8 (clone, Biolegend), anti-CD3 (clone, eBioscience),
and the MHC class-I tetramers, H2Kb-(SV40Tag LIWI-
PALL) and H2Kb-(Mesothelin AGINNLDNL), both from
the NIH tetramer core facility. Flow cytometry was per-
formed using a FACSCanto II (BD Bioscience) and data
were analysed using FlowJo software (Tree Star, Inc.).
Statistical analysis
The difference between group proportions was based on
the Fisher exact test or unpaired student’s t-test with
equal SD. Survival curves were based on Kaplan-Meier
estimates. All statistical tests were two-sided and a 5 %
significance level was assumed for all tests. Graphs and
statistical analysis were performed using Prism software
version 6.0 (Graphpad Software, Inc. La Jolla, CA).
Results
oHSVs demonstrate broad cytotoxicity against in vitro
models of ovarian cancer
We evaluated the capacity of several oHSV (R3659,
G207, M032, and M002) at various dose concentrations
to achieve oncolysis in a variety of mouse and human
ovarian cancer cell lines. Using data generated by the
Alamar Blue assay, we were able to develop linear
regression from the dose response plots. The paired hu-
man chemo-sensitive (CS) and chemo-resistant (CR) cell
lines and MISIIR transgenic mouse cancer cells all dem-
onstrated susceptibility to the anti-tumor cytotoxicity of
oHSV in vitro. Certain murine cell lines were more
sensitive to the cytotoxic effects of oHSV, with STOSE
and ID8 demonstrating extensive cytotoxicity across all
evaluated viruses (Fig. 1a). The MISIIR cell line appeared
less sensitive to oHSV; however, an anti-tumor effect
was still observed at higher virus concentrations. The
mean PFU/TD50 (averaged for each experiment which
was repeated twice) for each virus with the standard
deviation is demonstrated for each evaluated murine
ovarian cancer cell line (Fig. 1b). Within the human CS
lines, SKOV3ip1 and A2780ip2 demonstrated greater
cytotoxicity to all oHSVs when compared to HEYA8. All
three human CR cell lines were exquisitely sensitive to
oHSV, with A2780cp20 and SKOV3TR being the most
susceptible to M032 (Fig. 2a). The mean PFU/TD50
(averaged for each experiment which was repeated
twice) for each virus is demonstrated for the human
ovarian cancer cell lineages (Fig. 2b).
oHSV demonstrates decreased rates of metastatic ovarian
cancer in in vivo models
To assess the ability of oHSV to modulate overall
survival and tumor response in a spontaneous model of
ovarian carcinoma, MISIIR mice were randomized to
receive 3 weekly IP injections of M002 or PBS. Mice
were observed until they exceeded their clinical endpoint
(counted as death) or were euthanized at the designated
6 month study end. In the experimental cohort (M002
treated) only 2 mice developed metastatic disease; one
was euthanized on post-operative day 63 and was found
to have tumor weighing 2.0 g, the other was euthanized
at the 6 month endpoint and had occult 3.39 g of tumor
without ascites. Five (45.5 %) mice treated with M002
were euthanized at 6 months and did not have any
evidence of metastatic tumor. Within the control group
(PBS), two of the mice were euthanized at 6 months and
were found to have ascites and tumors weighing 1.9 g
and 0.53 gm, respectively. The remaining seven control
mice were euthanized with metastatic disease and had
tumor weights ranging from 0.14 to 7.8 gm (Fig. 3).
Compared to the control group, mice treated with M002
were less likely to develop metastatic ovarian cancer
(81.2 % vs 18.2 %; p = 0.008) and had a significantly
longer OS (p = 0.02; Fig. 4). Seven (77.8 %) control mice
had ascites at the time of necropsy compared to one
(9 %) mouse treated with oHSV. One mouse treated
with M002 died on post-operative day 21 of unknown
causes; however, there was no evidence of tumor at
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necropsy. Three (27.3 %) mice treated with M002
developed torticollis and were ultimately euthanized on
post-operative days 27, 37, and 60 secondary to declin-
ing body condition scoring. This was in comparison to 1
control mouse euthanized on post-operative day 55,
secondary to declining body condition score, which ex-
hibited metastatic disease at time of necropsy.
oHSV demonstrates robust tumor antigen-specific CD8+
T-cell immune response within the peritoneal cavity
To evaluate the tumor antigen-specific CD8+ T-cell im-
mune response, additional MISIIR mice were random-
ized to receive 3 weekly IP injections of the IL-12
expressing oHSV, M002, or PBS. 7 or 10 days following
the 3rd injection, the mice were euthanized and the
number of tumor antigen-specific CD8+ T-cells in the
omentum, peritoneal cavity, lymph nodes, and spleen
were quantified. When compared to the control mice,
mice injected with M002 demonstrated a more robust
tumor antigen-specific CD8+ T-cell immune response in
most evaluated tissues for both days 7 and 10.
A robust immune response in mice treated with M002
was observed within the day 7 cohort. The day 7 flow cy-
tometry numbers of tumor antigen-specific CD8+ T-cells
for the SV40-TAg and Mesothelin tetramers in the omen-
tum are illustrated for mice treated with IP M002 (Fig. 5a)
and PBS (Fig. 5b). The number of tumor antigen-specific
CD8+ T-cells was significantly higher for the SV40-TAg in
the omentum and to mesothelin in both the omentum
and peritoneal cavity. Specifically, the number of tumor
antigen-specific CD8+ T-cells to the SV40-TAg in the
omentum was 24.8 vs 10.5 (p = 0.04) and the number of
tumor antigen-specific CD8+ T-cells to mesothelin in
the omentum and peritoneal cavity were 359.1 vs 105.0
(p = 0.002) and 178.0 vs 85.3 (p = 0.02) respectively. While
not significant a more pronounced immune response in
a
b
Fig. 1 In vitro 4 h cytotoxicity of oHSV towards murine ovarian cancer cell lines. 48 h after M002 was added to the incubating murine cell lines,
Alamar Blue dye was added to each well. 4 and 8 h after the Alamar Blue dye was added to the wells, the mean optical density for each well
was calculated and used to construct a dose response plot and the number of viable cells was calculated utilizing regression analysis. A
representative figure at 4 h demonstrates the cytotoxicity of M002 towards the syngeneic murine cell lines (a), and the mean number of PFU/
TD50 at 4 and 8 h is demonstrated (b)
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mice treated with M002 was observed in both the
lymph nodes and spleen towards the Mesothelin
tetramer (Fig. 5c).
Similar to the analysis of the day 7 cohort, M002
treated mice euthanized and analyzed at day 10 demon-
strated an increased immune response within the
peritoneal cavity compared to mice treated with PBS.
The day 10 flow cytometry numbers of tumor antigen-
specific CD8+ T-cells for the SV40-TAg and mesothelin
tetramers in the omentum are illustrated for mice
treated with IP M002 (Fig. 6a) and PBS (Fig. 6b). The
number of tumor antigen-specific CD8+ T-cells to the
mesothelin-tetramer in the peritoneal cavity was signifi-
cantly higher in mice treated with M002 compared to
mice treated with PBS, 1009.0 vs 246.0 (p = 0.03).
Although not significant, the number of tumor antigen-
specific CD8+ T-cells to the SV40-TAg-tetramer and
mesothelin-tetramer in the omentum, peritoneal cavity,
and lymph nodes was more potent in mice treated with
M002 (Fig. 6c).
Discussion
Oncolytic viruses are an emerging immunotherapeutic
approach for cancer as demonstrated by the recent FDA
approval of talimogene laherparepvec (T-VEC) (Amgen,
Imlygic®), the first FDA-approved oncolytic virus therapy
for the treatment of advanced and unresectable melan-
oma [23]. Studies utilizing oncolytic reovirus, measles
vaccine virus, vaccinia virus, vesicular stomatitis virus,
and adenovirus have demonstrated the feasibility of this
approach for ovarian cancer [40]. HSV is another
reasonable oncolytic to evaluate for the treatment of
ovarian cancer. Our translational pilot study provides
preliminary evidence supporting that oHSV may be an
effective treatment agent for women with ovarian cancer.
In our study, all evaluated oHSVs (R3659, G207, M032,
and M002) demonstrated a cytotoxic effect in vitro to a
variety of mouse and human ovarian cancer cell lines.
Although some cell lines demonstrated greater sensitivity
to oHSV (STOSE, Ig10, M0505, & A2780cp20), a cyto-
toxic anti-tumor effect was observed across all lineages.
a
b
Fig. 2 In vitro 4 h cytotoxicity of oHSV towards human ovarian cancer cell lines. 48 h after M032 was added to the incubating murine cell lines,
Alamar Blue dye was added to each well. 4 and 8 h after the Alamar Blue dye was added to the wells, the mean optical density for each well
was calculated and used to construct a dose response plot and the number of viable cells was calculated utilizing regression analysis. A
representative figure at 4 h demonstrates the cytotoxicity of M032 towards the human ovarian cancer cell lines (a), and the mean number of
PFU/TD50 at 4 and 8 h is demonstrated (b)
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Importantly, each oHSV demonstrated an anti-tumor
response towards the three human CR cell lines. Since our
cytotoxicity studies were performed in vitro, it is not
surprising that the “armed” oHSV did not outperform the
“unarmed” viruses. In our preliminary in vivo studies, IP
injection of M002 was associated with a significant
improvement in OS when compared to IP injection with
PBS. A significant difference in the number of mice that
died with metastatic ovarian cancer was observed between
the two cohorts. Furthermore, treatment with 3 weekly
doses of M002 led to less accumulation of ascites. IP
injection with M002 was reasonably tolerated. Although
three mice in the experimental cohort developed torticol-
lis, this was not significantly different from the control
group. The basis for this head and neck dystonia was not
readily apparent, and we recognize that it is much higher
than the observed rate of 2 % of transgene positive MISIIR
mice within our breeding colony. We cannot state that
either the virus or the IL-12 could have caused this
change. Although we did not examine the inner ear, the
brain or brain stem in these mice, we would speculate that
non-infected metastatic ovarian tumor cells, escaping
from the peritoneum, might have been the cause. In future
studies, complete necropsies of mice exhibiting head tilt
will be conducted to establish the basis. The dose used in
this study was based upon previous work that demon-
strated maximum LD50 without increased toxicity [12]. It
is yet to be determined if smaller doses of virus would be
as efficacious.
The results of our studies are similar to that of others.
Specifically, preclinical studies have demonstrated that
IP injection of HSV-1716-infected PA-1 carrier cells led
to a significant tumor reduction in SCID mice that had
been inoculated with A2780 cells and a significant
prolongation of median survival in SCID mice bearing
SKOV3 tumors (17 weeks vs 9 weeks) [21]. Utilizing a
murine syngeneic model of ovarian cancer, Benencia et
al. demonstrated that intratumoral injection of
HSV-1716 resulted in reduction of tumor growth and a
significant survival advantage [41]. Additionally, Coukos
and colleagues demonstrated that IP injection of HSV-
G207, a recombinant HSV-1 lacking the infected cell
products 34.5 and 6, which enhances tumor cell selectiv-
ity, was associated with a significant reduction in tumor
volume and tumor spread in an in vivo mouse xenograft
model of ovarian cancer [22]. To further the therapeutic
potential of replication-selective viruses, Fu et al.
constructed an oncolytic virus from HSV-2 by deleting
the protein kinase domain of the viral ICP10 gene, which
targets the Ras signaling pathway in tumor cells. HSV-2
was injected IP into nude mice bearing metastatic human
ovarian tumor xenografts and demonstrated complete
tumor abolition in 87 % of the mice [42]. Wang and col-
leagues demonstrated that HSV-1 thymidine kinase medi-
ated gene transfer was superior to adenoviral vectors and
required lower does in vitro, supporting HSV-1 as a cap-
able and alternative vector for ovarian cancer gene therapy
[43]. There is currently a phase I trial (NCT01997190)
evaluating AdV-tk (Advantagene, Inc), an oncolytic herpes
simplex virus in patients with malignant pleural effusions
and solid tumors, including ovarian cancer. The optimal
use of adjuvant IL-12 in women with advanced ovarian
cancer has not been determined. For example, Lenzi el al.
evaluated IP rIL-12 in women with advanced ovarian
cancer who completed platinum-based chemotherapy and
Fig. 3 Anti-tumor effect in MISIIR-TAg mice treated with IP M002 or
PBS in vivo MISIIR mice were injected with IP M002 or PBS weekly for a
total of three doses. They were followed until death at which time a
necropsy was performed to determine the presence and extent of
tumor burden. The weight of each mouse’s tumor is depicted. Each
circle represents a mouse treated with IP PBS, whereas each square
represents a mouse treated with IP M002. Two (18 %) mice treated
with PBS were without evidence of tumor compared to 9 (81 %) mice
treated with M002 (p = 0.055)
Fig. 4 Overall survival in MISIIR-TAg mice treated with IP M002 or PBS.
MISIIR mice were observed following 3 weekly treatments with IP M002
or PBS. Necropsy was performed at time of death evaluating for the
presence of metastatic ovarian carcinoma. If the mice were still alive at
6 months, a planned euthanasia date to evaluate for metastatic disease
was predetermined prior to mouse randomization. Mice treated with
M002 had a significantly improved overall survival compared to those
treated with placebo (p= 0.02)
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underwent a second look surgery. Women with ≤ 1 cm
residual disease were treated with IP rIL-12 at weekly
intervals with a treatment range of only 1 to 16 weeks. Of
11 women that were assessed, 2 had stable disease while 9
had progressive disease. Although the response rate was
worse than anticipated, this patient population did signifi-
cantly worse than what is traditionally observed in women
with optimally debulked ovarian cancer [44]. Future
studies exploring the optimal patient population with
advanced ovarian cancer, tumor biology/histology, pleio-
trophic effects of IL-12, and combining IL-12 with oncoly-
tic virus are warranted.
The omentum has several immunogenic roles xme-
diated primarily by filtering peritoneal fluid, pathogens,
antigens, and cells, including metastasizing ovarian
cancer cells [45, 46]. The omentum contains a variety of
immune cells (T cells, B cells, and dendritic cells) that
are clustered in milky spots embedded between adipo-
cytes. These milky spots detect peritoneal antigens and
generate immune responses but also make them an ideal
site for collecting metastases from peritoneal cancers.
Metastatic tumor cells have been demonstrated in the
omentum in MISIIR mice as early as 7 weeks. One
might expect that if tumor cells are trapped in milky
spots and milky spots are immune inductive sites, then
the omentum should trigger an anti-tumor immune re-
sponse. However, Tregs also accumulate in the omentum
of mice together with metastatic carcinoma, suggesting
that the omentum may be a site of immune suppression
rather than immune activation. Additionally, specialized
populations of Tregs reside in visceral adipose tissue,
including the omentum. These Tregs are dependent on
the transcription factor PPARg and are profoundly
suppressive. In addition, innate lymphocyte cells (ILCs)
that make IL-13 also reside in the omentum. Both the
ILCs and the Tregs are likely to suppress anti-tumor
immunity [47–52]. Via this filtering process, milky spots
within the omentum are ideal sites for peritoneal cancer
cells to collect and influence the host immune response
[15, 16, 53]. The microenvironments of the omentum
and peritoneal cavity are unique milieu’s that can poten-
tially be altered for therapeutic gains. Agents that modify
or reverse this process may lead to improved outcomes
in women with ovarian cancer. Our results demonstrate
a c
b
Fig. 5 Day 7 tumor antigen-specific CD8+ T cell immune response. MISIIR mice were treated with either IP M002 or PBS weekly for a total of 3 weeks. Mice
were subsequently euthanized on day 7 or day 10 following the third injection. A representative day 7 flow cytometry gate demonstrating the number of
tumor antigen-specific CD8+ T-cells for the Mesothelin tetramer in the omentum is illustrated for mice treated with M002 (a) and PBS (b). The day 7 tumor
antigen-specific CD8+ T-cell immune response for the SV40-TAg and Mesothelin tetramer from the omentum, peritoneal fluid, draining lymph nodes, and
spleen is demonstrated. The number of antigen-specific CD8+ T-cells was significantly larger to the SV40-TAg in the omentum (p= 0.04) and to Mesothelin
in the omentum (p= 0.002) and peritoneal cavity (p= 0.02) (c)
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that IP treatment with the murine IL-12 expressing
oHSV, M002, was associated with a more robust local
immune response as demonstrated by higher numbers
of tumor antigen-specific CD8+ T-cells within the omen-
tum and peritoneal cavity. Compared to mice treated
with PBS, mice treated with M002 demonstrated an
increased immune response at both 7 and 10 days fol-
lowing their last of 3 weekly injections. Treatment with
M002 was also associated with increased tumor antigen-
specific CD8+ T-cells within the spleen and draining
lymph nodes, however it was not as significant, suggest-
ing that the omentum and peritoneal cavity were the
primary immune effector sites of the oHSV regardless of
timing from last IP injection.
In summary, our data demonstrate that “unarmed”
and IL-12 “armed” oHSV produce a vigorous cytotoxic
effect across a host of ovarian cancer cell lines in vitro.
Furthermore, MISIIR mice treated with IP injections of
M002 had significantly lower rates of metastatic ovarian
cancer and improved survival. Finally, a more robust
tumor antigen-specific CD8+ T-cell immune response
was demonstrated in most tissues treated with oHSV
compared to placebo, in spite of limited data defining
the optimal M002 dose or schedule. We recognize that
additional more in depth studies are required to further
clarify the benefit of using an IL-12 expressing oHSV
over an unarmed oHSV and to more comprehensively
assess the immune response. Additionally, studies evalu-
ating the optimal dosing strategy, characterizing at the
molecular level the genetic determinants of sensitivity to
oHSV, and assessing novel immunotherapy combination
approaches with oHSV appear to be warranted. Never-
theless, this preliminary study demonstrates the poten-
tial of an IL-12 expressing oHSV in this disease context.
Conclusion
Our translational pilot study demonstrates that an
IL-12-expressing oHSV effectively kills both murine and
human ovarian cancer cell lines in vitro and it promotes
tumor antigen-specific CD8+ T-cell responses in the
peritoneal cavity and omentum. IP injection with M002
appears to be associated with reduced peritoneal metas-
tasis and improved survival in a murine ovarian cancer




Fig. 6 Day 10 tumor antigen-specific CD8+ T cell immune response. MISIIR mice were treated with either IP M002 or PBS weekly for a total of 3 weeks.
Mice were subsequently euthanized on day 7 or day 10 following the third injection. A representative day 10 flow cytometry gate demonstrating the
numbers of tumor antigen-specific CD8+ T-cells for the Mesothelin tetramer in the omentum is illustrated for mice treated with M002 (a) and PBS (b).
The day 10 tumor antigen-specific CD8+ T-cell immune response for the SV40-TAg and Mesothelin tetramer from the omentum, peritoneal
fluid, draining lymph nodes, and spleen is demonstrated. The number of antigen-specific CD8+ T-cells was significantly larger to Mesothelin in
the peritoneal cavity (p = 0.03) (c)
Thomas et al. Journal of Ovarian Research  (2016) 9:70 Page 9 of 11
most lethal gynecologic malignancy in the United States.
Despite enhancement in conventional surgical debulking
and chemotherapy, most women with advanced disease
eventually recur and ultimately die from metastatic dis-
ease. To date there are no FDA approved oncolytic vi-
ruses for the treatment of ovarian cancer. Consequently,
developing novel treatments, such as oncolytic viruses,
for women with epithelial ovarian cancer are of upmost
importance for women with this disease.
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